Quick Answer
Zentalis Pharmaceuticals, Inc. reported Operating Income Loss of -$152.81 million for the year ending 2025.
- Zentalis Pharmaceuticals, Inc. showed an increase of +20.1% in Operating Income Loss from 2024 to 2025.
- This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$8.72 million | Q2 2019: -$10.64 million | Q3 2019: -$12.58 million | Q4 2019: -$14.91 million | Q1 2020: -$16.40 million | Q2 2020: -$27.38 million | Q3 2020: -$34.77 million | Q4 2020: -$40.25 million | Q1 2021: -$50.35 million | Q2 2021: -$55.13 million | Q3 2021: -$62.87 million | Q4 2021: -$48.19 million | Q1 2022: -$57.88 million | Q2 2022: -$63.46 million | Q3 2022: -$54.19 million | Q1 2023: -$64.95 million | Q2 2023: -$103.92 million | Q3 2023: -$62.72 million | Q1 2024: -$24.77 million | Q2 2024: -$65.15 million | Q3 2024: -$51.43 million | Q1 2025: -$45.62 million | Q2 2025: -$36.06 million | Q3 2025: -$33.73 million.
- Over the full 7 years of available data (2019 to 2025), Zentalis Pharmaceuticals, Inc.'s Operating Income Loss has declined by 226.2%.
- Historical annual values: Fiscal year 2025: -$152.81 million | Fiscal year 2024: -$191.19 million | Fiscal year 2023: -$299.51 million | Fiscal year 2022: -$227.29 million | Fiscal year 2021: -$216.54 million | Fiscal year 2020: -$118.79 million | Fiscal year 2019: -$46.85 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: